STOCK TITAN

Gilead (GILD) executive sells 28,000 shares, exercises 25,000 options

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Gilead Sciences Chief Comm & Corp Aff Officer Johanna Mercier reported option exercises and share sales. On May 15, 2026, she exercised 25,000 non-qualified stock options at an exercise price of $66.64 per share and acquired the same number of common shares.

That day she also completed open-market sales totaling 28,000 shares of Gilead common stock in multiple trades at prices ranging from about $129.66 to $132.78 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025. Following these transactions, she directly holds 125,779 common shares and retains 23,110 stock options with a $66.64 exercise price expiring on July 24, 2029.

Positive

  • None.

Negative

  • None.
Insider Mercier Johanna
Role Chief Comm & Corp Aff Officer
Sold 28,000 shs ($3.68M)
Type Security Shares Price Value
Exercise Non-qualified Stock Option (Right to Buy) 25,000 $0.00 --
Exercise Common Stock 25,000 $66.64 $1.67M
Sale Common Stock 7,749 $130.2915 $1.01M
Sale Common Stock 11,177 $131.1917 $1.47M
Sale Common Stock 8,374 $132.2324 $1.11M
Sale Common Stock 700 $132.7514 $93K
Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 23,110 shares (Direct, null); Common Stock — 153,779 shares (Direct, null)
Footnotes (1)
  1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Sale prices for the transactions reported range from $129.66 to $130.63. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Sale prices for the transactions reported range from $130.67 to $131.505. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Sale prices for the transactions reported range from $131.71 to $132.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Sale prices for the transactions reported range from $132.74 to $132.78. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Shares sold 28,000 shares Total open-market sales on May 15, 2026
Options exercised 25,000 shares Non-qualified stock options converted to common stock
Exercise price $66.64 per share Non-qualified stock option exercise price
Sale price range $129.66–$132.78 per share Price ranges from sale footnotes F2–F5
Shares held after 125,779 shares Direct common stock holdings after final sale
Remaining options 23,110 options Non-qualified stock options remaining after 25,000 exercised
Option expiration July 24, 2029 Expiration date of non-qualified stock option grant
Rule 10b5-1 trading plan regulatory
"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-qualified Stock Option (Right to Buy) financial
"security_title: "Non-qualified Stock Option (Right to Buy)" for the derivative transaction."
open-market sale financial
"transaction_action: "open-market sale" with transaction code "S" for common stock."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security" for code "M"."
four-year vesting schedule financial
"The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mercier Johanna

(Last)(First)(Middle)
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE

(Street)
FOSTER CITY CALIFORNIA 94404

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Comm & Corp Aff Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/15/2026M(1)25,000A$66.64153,779D
Common Stock05/15/2026S(1)7,749D$130.2915(2)146,030D
Common Stock05/15/2026S(1)11,177D$131.1917(3)134,853D
Common Stock05/15/2026S(1)8,374D$132.2324(4)126,479D
Common Stock05/15/2026S(1)700D$132.7514(5)125,779D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-qualified Stock Option (Right to Buy)$66.6405/15/2026M(1)25,000 (6)07/24/2029Common Stock25,000$023,110D
Explanation of Responses:
1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
2. Sale prices for the transactions reported range from $129.66 to $130.63. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
3. Sale prices for the transactions reported range from $130.67 to $131.505. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
4. Sale prices for the transactions reported range from $131.71 to $132.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
5. Sale prices for the transactions reported range from $132.74 to $132.78. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
6. The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Remarks:
/s/ Amy Kim by Power of Attorney for Johanna Mercier05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Gilead (GILD) executive Johanna Mercier report in this Form 4?

Johanna Mercier reported exercising 25,000 stock options and selling 28,000 Gilead common shares. The transactions occurred on May 15, 2026, and involved open-market sales executed under a pre-arranged Rule 10b5-1 trading plan adopted earlier in February 2025.

How many Gilead (GILD) shares did Johanna Mercier sell and at what prices?

She sold a total of 28,000 Gilead common shares in several open-market trades. Sale prices ranged from approximately $129.66 to $132.78 per share, according to the reported price ranges disclosed in multiple transaction footnotes attached to the Form 4 filing.

What options did Johanna Mercier exercise in Gilead (GILD) stock?

She exercised 25,000 non-qualified stock options to buy Gilead common stock at an exercise price of $66.64 per share. These options are part of an award with a four-year vesting schedule and an expiration date of July 24, 2029.

How many Gilead (GILD) shares does Johanna Mercier hold after these transactions?

After the reported option exercise and share sales, Johanna Mercier directly holds 125,779 shares of Gilead common stock. This post-transaction holding reflects her remaining direct equity stake as shown in the share balance following the final reported sale entry.

Were Johanna Mercier’s Gilead (GILD) share sales pre-planned?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Such plans pre-schedule trades, meaning timing decisions are set in advance rather than being made in response to short-term market developments.

What Gilead (GILD) stock options does Johanna Mercier still hold?

Following the 25,000-option exercise, she retains 23,110 non-qualified stock options. These options carry a $66.64 exercise price and have an expiration date of July 24, 2029, according to the derivative transaction details included in the Form 4 data.